Dermatology Times

APRIL 25, 2025

Alexandra Golant, MD, discusses how advancements in pediatric atopic dermatitis (AD) treatment, including topical Janus kinase (JAK) inhibitors like ruxolitinib, may reshape guidelines, yet hurdles remain in regulatory approval, safety data, and accessibility. Adoption depends on efficacy, cost, insurance, and caregiver education.

Dermatitis 36

Dermatitis Treatments Therapy Safety 36

Dermatology Times

APRIL 21, 2025

Eichenfield discusses safety, lab monitoring, and treatment positioning of icotrokinra in adolescents with moderate to severe plaque psoriasis.

Safety 69

Safety Treatments 69

The Dermatology Digest

DECEMBER 4, 2024

Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Restem’s umbilical cord outer lining stem cells (ULSCs) program for the treatment of dermatomyositis (DM) and polymyositis (PM). The estimated incidence of PM/DM is approximately 5 to 22 cases per 100,000 individuals. PHOTO CREDIT: DermNet The post U.S.

Treatments 36

Treatments Office Therapy Clinic 36

The Dermatology Digest

MAY 9, 2025

Icotrokinra, Johnson & Johnsons investigational oral interleukin(IL)-23 blocker, shows significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis, according to new Phase 3 data presented at the 2025 Society for Investigative Dermatology (SID) Annual Meeting in San Diego, CA.

Safety 36

Safety Dermatology Innovations Treatments 36

The Dermatology Digest

SEPTEMBER 27, 2024

Epicutis is launching its Arctigenin Brightening Treatment in October 2024, and the Dermatology Digest got an exclusive sneak peek of the serum. Arctigenin Brightening Treatment is EWG Verified , meaning that the product meets EWG’s strictest standards for health and safety. in an interview with TDD.

Vitamin C 74

Vitamin C Treatments Extractions Safety 74

The Dermatology Digest

FEBRUARY 18, 2025

Food and Drug Administration (FDA) approved mirdametinib (Gomekli, SpringWorks) for the treatment of adult and pediatric patients aged two and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) that are not amenable to complete resection. Gomekli is an oral, small molecule MEK inhibitor.

Networking 64

Networking Safety Innovations Management 64

The Dermatology Digest

MARCH 3, 2025

” A double-blinded, randomized, placebo-controlled trial evaluated the safety and efficacy of BioRewind in 104 patients over 12-weeks. ”: The post This Week’s Hottest Drops, Launches, and Collabs appeared first on The Dermatology Digest. We are confident this innovation will redefine how we think about skin health.”

Medical Grade Skincare 74

Medical Grade Skincare Social Media Branding Skin Health 74

Dermatology Times

JUNE 10, 2024

Amy Paller, MD, reviews the various types of therapeutics available and coming soon for pediatric atopic dermatitis and how she decides what treatment approach is best for each patient.

Safety 73

Safety Treatments Dermatitis 73

US Dermatologt Partners

JANUARY 13, 2025

Dermatology Partners Fairfax , Whether patients are dealing with persistent blackheads, painful cystic acne, or stubborn whiteheads, the temptation to pop or pick at acne is hard to resist. Acne extractions also make it possible for acne treatments to be more effective because they are able to penetrate into pores more easily.

Extractions 41

Extractions Scarring Pores Chemical Peels 41

The Dermatology Digest

JANUARY 8, 2025

Medical spas in Las Vegas, NV, lack on-site physician supervision, according to a study by the the American Society for Dermatologic Surgery Association (ASDSA). Of the 63 medical spas reviewed, 73% of treatments involving injections were performed by non-physicians. Laurin Council, MD, MBA, ASDS/A President, in a news release.

Medical 36

Medical Social Media Safety Training 36

The Dermatology Digest

MARCH 5, 2025

first pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) trial of Xyngari, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. The XYNGARI Phase 3 STAR-1 clinical study will evaluate the efficacy, safety, and tolerability of Xyngari in patients with moderate-to-severe facial acne.

Treatments 36

Treatments Rosacea Pores Office 36

The Dermatology Digest

JULY 24, 2024

Stelara is a currently approved treatment for adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderately to severely active Crohn’s, and moderately to severely active ulcerative colitis.

Dermatology 78

Dermatology Sales Marketing Safety 78

Lipgloss and Aftershave

NOVEMBER 1, 2024

Jenni Nagle, L+A CO-Founder had a CO2 laser treatment and kept an eight day diary of her recovery process! For estheticians and skincare professionals, addressing pigmentation involves understanding and applying a multimodality treatment approach, which combines various techniques to tackle pigmentation through multiple mechanisms.

Chemical Peels 52

Chemical Peels Hyperpigmentation Vitamin C Microneedling 52

The Dermatology Digest

DECEMBER 11, 2024

Despite disappointing efficacy, ANB032 was well tolerated with no safety signals observed, the Company reported. The ARISE-AD study evaluated the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ANB032 monotherapy in patients with moderate-to-severe AD.

Safety 36

Safety Dermatitis Therapy Dermatology 36

The Dermatology Digest

APRIL 7, 2024

A newly developed therapeutic ladder can help guide dermatologists and patients on the use of nonsteroidal treatment options for atopic dermatitis (AD). Nonsteroidal treatment options for AD have rapidly expanded in recent years with the development of phosphodiesterase-4 inhibitors, biologics, and Janus kinase (JAK) inhibitors.

Treatments 77

Treatments Dermatitis Therapy Medical 77

The Dermatology Digest

MARCH 18, 2025

has completed enrollment in its Phase 3 clinical trial evaluating aminolevulinic acid hydrochloride (Ameluz) with photodynamic therapy (PDT) for the treatment of mild to moderate actinic keratoses (AKs) on the extremities, neck, and trunk. They are then followed up for approximately one year after the last PDT treatment.

Treatments 36

Treatments Dermatology Safety Therapy 36

The Dermatology Digest

APRIL 27, 2025

that it placed a clinical hold on its Phase 1b study evaluating VYN202 for the treatment of moderate-to-severe plaque psoriasis. FDA Places Hold on VYNEs VYN202 Phase 1b Trial in PsO appeared first on The Dermatology Digest. Food and Drug Administration (FDA) has verbally informed VYNE Therapeutics Inc.

Clinic 41

Clinic Office Safety Dermatology 41

Dermatology Times

JANUARY 9, 2024

Experts in dermatology highlight the crucial role of setting treatment response expectations and stress the need for discussions on managing mild plaque psoriasis, highlighting the utilization of systemic therapies in this context.

Safety 77

Safety Education Therapy Management 77

The Dermatology Digest

MARCH 8, 2025

The research was presented as a late-breaker at the 2025American Academy of Dermatology(AAD) Annual Meeting inOrlando, FL. The Phase 3 TRuE-PN clinical trial program comprises TRuE-PN1 and TRuE-PN2 studies, which evaluate the safety and efficacy of twice-daily ruxolitinib cream 1.5% The overall safety profile of ruxolitinib cream 1.5%

Safety 36

Safety Clinic Therapy Dermatology 36

Dermatology Times

APRIL 12, 2024

She also addresses potential drug interactions, focusing on the safety of dupilumab in systemic treatment. Dr Alexandra Golant discusses managing multiple conditions in a 17-year-old African American waitress, highlighting the complexities of treating moderate-to-severe atopic dermatitis alongside severe acne and oral contraceptives.

Dermatitis 85

Dermatitis Treatments Safety Management 85

The Dermatology Digest

FEBRUARY 17, 2025

Considering risks vs. benefits of cosmetic treatments While four in 10 parents, and more mothers than fathers, say they know someone who has had a non-surgical cosmetic procedure, just 7% of parents of teen girls compared to 1% of parents of teen boys say their teen has asked about getting one.

Social Media 57

Social Media Hair Removal Safety Surgery 57

The Dermatology Digest

NOVEMBER 30, 2024

Several new therapies are coming down the pike for the treatment of lichen planus, a chronic inflammatory condition that affects an estimated 1% to 2% of the global population, according to a new report from Research and Markets. Incyte is investigating the efficacy and safety of ruxolitinib cream in cutaneous lichen planus.

Pharmaceutical 36

Pharmaceutical Safety Marketing Therapy 36

Dermatology Times

NOVEMBER 5, 2024

As news of benzene contamination in benzoyl peroxide products continues to raise safety discussions, Steve Xu, MD, MSc, advocates for stricter regulations, increased research, and the consideration of safer acne treatment alternatives.

Treatments 73

Treatments Safety 73

The Dermatology Digest

MARCH 10, 2025

improves moderate-to-severe nail psoriasis, according to new research presented at the 2025American Academy of Dermatology(AAD) Annual Meeting in Orlando, FL. ” The post Tildrakizumab (Ilumya, Sun Pharma) Improves Moderate-to-severe Nail PsO appeared first on The Dermatology Digest.

Pharmaceutical 36

Pharmaceutical Safety Clinic Injections 36

The Dermatology Digest

JANUARY 10, 2025

Specifically, CGB-500 had an 8-week treatment success of 95% (Investigator’s Global Assessment or IGA core of “0” or “1” and > 2 grade improvement ). This larger Phase 2b trial (n=180) will focus on optimizing dosing regimens and further assessing the safety and efficacy of CGB-500.

Dermatitis 36

Dermatitis Safety Technology Dermatology 36

The Dermatology Digest

JANUARY 8, 2025

topical ET-02 may be more effective than existing treatments for androgenic alopecia, according to results of a first-in-man clinical trial. A final assessment of the subjects was made one week after the treatments ended. Key results of the study showed: Safety: ET-02 was found to be safe and well tolerated.

Safety 36

Safety Clinic Pharmaceutical Treatments 36

Lipgloss and Aftershave

APRIL 21, 2025

With advancements in formulation technology, time-honored plant ingredients are now precision-engineered to deliver measurable results in even the most advanced treatment protocols. Uses real-time temperature feedback for safety. For Soothing + Restoring Calendula Calms post-treatment irritation. Quantum 10 = jawline + arms.

Technology 52

Technology Post-Op Microneedling Collagen 52

The Dermatology Digest

FEBRUARY 25, 2025

This announcement follows the successful completion of a Phase I clinical trial involving 40 healthy volunteers, where ruxoprubart demonstrated promising results and a clean safety profile, with no serious adverse events reported. FDA Approves IND for Ruxoprubart in DM appeared first on The Dermatology Digest. The post U.S.

Safety 36

Safety Therapy Clinic Dermatology 36

Dermatology Times

MAY 13, 2024

5 experts share insights on long-term safety, efficacy, demographic variances, and more in pediatric AD.

Safety 74

Safety Treatments 74

The Dermatology Digest

APRIL 11, 2025

anhydrous gel is showing promise in the treatment of microcystic lymphatic malformations (microcystic LMs), according to a presentation at the 15th World Congress of Pediatric Dermatology in Buenos Aires, Argentina. Anhydrous Gel Shows Promise for Microcystic LMs appeared first on The Dermatology Digest. s QTORIN rapamycin 3.9%

Therapy 36

Therapy Dermatology Office Clinic 36

Dermatology Times

DECEMBER 18, 2024

The new research identified notable improvements in disease severity, sweat reduction, and quality of life for patients treated with sofpironium.

Safety 64

Safety Treatments 64

The Dermatology Digest

DECEMBER 3, 2024

The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization in Great Britain for delgocitinib cream (Anzupgo, Leo Pharma) for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate.

Marketing 36

Marketing Eczema Safety Management 36

The Dermatology Digest

NOVEMBER 18, 2024

Safety data was found to be consistent with the Phase 2 FRONTIER 1 and 2 studies. of participants experiencing a treatment emergent adverse event (TEAE) at week 16. ” The post PsO Pipeline Update: Icotrokinra, an Oral IL-23 Blocker, Looks Good in Topline Phase 3 Data appeared first on The Dermatology Digest.

Safety 36

Safety Medical Innovations Dermatology 36

The Dermatology Digest

JANUARY 22, 2025

for review for the topical treatment of scalp and body psoriasis in patients aged 12 and up. Safety and Tolerability:Roflumilast foam was well tolerated across studies, with treatment-emergent adverse events (TEAEs) predominantly mild to moderate in severity. for the treatment of seborrheic dermatitis in patients 9 and older.

Dermatitis 36

Dermatitis Safety Treatments Dermatology 36

Southeastern Esthetics Institute

AUGUST 23, 2016

Having a thorough understanding of the dermatology and plastic surgery procedures, in addition to all new and modern cosmetic procedures on the market, is critical in assisting your clients in answering questions. Having daily and weekly communication when dealing with patients receiving treatment is critical.

Esthetician 195

Esthetician Esthetics Document Office 195

Texas Dermatology

JANUARY 26, 2025

At Texas Dermatology, we offer Botox and Dysport as two of the most popular non-surgical solutions for smoothing fine lines and wrinkles, helping you achieve a refreshed, youthful appearance. Both treatments are FDA-approved and trusted for their safety, effectiveness, and natural-looking results.

Wrinkles 36

Wrinkles Injections Med Spa Safety 36

The Dermatology Digest

JULY 1, 2024

PYZCHIVA has been approved for the treatment of moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderately to severely active ulcerative colitis.

Portfolios 74

Portfolios Safety Clinic Injections 74